Results 71 to 80 of about 54,283 (258)

Visceral Leishmaniasis Treatment, Italy [PDF]

Emerging Infectious Diseases, 2003
First-line drug treatment was recorded in 573 immunocompetent patients with visceral leishmaniasis in Italy. In the past 12 years, the proportion of antimonial treatments decreased from 100% to 2.8%, while the proportion of amphotericin B treatments increased from 0% to 97.2%.
Luigi Gradoni, Marina Gramiccia, Aldo Scalone   +2 more
openaire   +3 more sources

Epidemiological aspects of human and canine visceral leishmaniasis in State of Alagoas, Northeast, Brazil

Brazilian Journal of Biology, 2018
Zoonotic visceral leishmaniasis (ZVL), caused by protozoans of the genus Leishmania, it is a worldwide of great importance disease. In the northeast region of Brazil, the state of Alagoas has an endemic status for ZVL.
M. A. N. Rocha, T. J. Matos-Rocha, C. M. B. Ribeiro, S. R. O. Abreu   +3 more
doaj   +1 more source

The Role of Foxes in Transmitting Zoonotic Bacteria to Humans: A Scoping Review

Zoonoses and Public Health, EarlyView.
ABSTRACT Zoonotic diseases inflict substantial burdens on human and animal populations worldwide, and many of these infections are bacterial. An Australian study investigating environmental risk factors for Buruli ulcer in humans detected the causative agent, Mycobacterium ulcerans, in the faeces of wild foxes, a novel finding that suggests foxes may ...
Emma C. Hobbs, Bridgette McNamara, Sarah Hayman, Kim Blasdell, Eugene Athan, Daniel P. O'Brien, Michael Muleme   +6 more
wiley   +1 more source

Rapid Detection of Leishmania infantum Infection in Dogs: Comparative Study Using an Immunochromatographic Dipstick Test, Enzyme-Linked Immunosorbent Assay, and PCR [PDF]

, 2002
Current zoonotic visceral leishmaniasis (ZVL) control programs in Brazil include the culling of Leishmania infantum-infected reservoir dogs, a strategy that has failed to prevent a rise of canine and human ZVL cases over the past decade.
Bruce Alex, Bruce Alex, Clive R. Davies, Clive R. Davies, J. Clin Microbiol, Richard Reithinger, Richard Reithinger, Rupert J. Quinnell, Rupert J. Quinnell   +8 more
core   +3 more sources

Leishmaniasis–HIV coinfection: current challenges

HIV/AIDS: Research and Palliative Care, 2016
José Angelo Lauletta Lindoso,1,2 Mirella Alves Cunha,3 Igor Thiago Queiroz,4 Carlos Henrique Valente Moreira2 1Laboratory of Soroepidemiology (LIM HC-FMUSP), São Paulo University, São Paulo, 2Instituto de Infectologia Emilio ...
Lindoso JAL, Cunha MA, Queiroz IT, Moreira CHV   +3 more
doaj  

Validated LC‐MS/MS Method for Quantifying the Antiparasitic Nitroimidazole DNDI‐0690 in Preclinical Target Site PK/PD Studies

Biomedical Chromatography, Volume 39, Issue 8, August 2025.
ABSTRACT Understanding the target site pharmacokinetics (PK) of the nitroimidazole analog DNDI‐0690, a potential drug for the neglected parasitic disease leishmaniasis, is important due to the diversity of infected tissue sites and potential drug penetration variability.
Wietse M. Schouten, Katrien van Bocxlaer, Hilde Rosing, Alwin D. R. Huitema, Jos H. Beijnen, Jadel M. Kratz, Charles E. Mowbray, Thomas P. C. Dorlo   +7 more
wiley   +1 more source

HIV-associated visceral leishmaniasis [PDF]

Clinical Microbiology and Infection, 2001
Visceral leishmaniasis (VL) is a severe disease caused by protozoa of the genus Leishmania that usually affects immunocompetent hosts in endemic areas [1,2]. Since the mid-1980s, VL has been recognized as an opportunistic infection associated with some immunodeficiency states, such as neoplasms, organ transplantation, or treatment with ...
Vicente Pintado, R. López-Vélez
openaire   +3 more sources

In Vitro Leishmanicidal Efficacy of Synthesized Arylidene Analogues of Glitazone

Drug Development Research, Volume 86, Issue 5, August 2025.
ABSTRACT Diabetes is a fast‐growing health issue in low‐ and middle‐income countries, with ~80% of diabetics living in the tropics and sub‐tropics. It is a deadly condition claiming the lives of millions of individuals annually, with no therapeutic treatment available to date. The management of diabetes is thus limited to symptomatic relief by glycemic
Janine Aucamp, Helena D. Janse van Rensburg, Simon S. Mnyakeni‐Moleele, Keisuke Suganuma, David D. N'Da   +4 more
wiley   +1 more source

Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda. [PDF]

, 2009
OBJECTIVE: To identify risk factors for in-hospital mortality in patients treated for visceral leishmaniasis (VL) in Uganda. METHODS: Retrospective analysis of VL patients' clinical data collected for project monitoring by Médecins Sans Frontières in ...
Bern, Bryceson, Chappuis, Collin, Croft, Delgado, Desjeux, Guerin, Jamjoom, Lyons, Moore, Mueller, Mueller, Olliaro, Ritmeijer, Ritmeijer, Seaman, Sundar, Thakur, Veeken, WHO   +20 more
core   +3 more sources

Appraising the visibility, relevance and impacts of clinical pharmacology

British Journal of Clinical Pharmacology, Volume 91, Issue 7, Page 1884-1898, July 2025.
Aims Clinical pharmacology (CP) used to be a strong medical and scientific field, but during the last three decades it seems to have lost some of its appeal. We reviewed the visibility, relevance and impact of CP and clinical pharmacologists across the globe and suggest ways to strengthen the discipline to address future pharmacotherapeutic challenges.
Serge Cremers, Samuel L. M. Arnold, Nilima A. Kshirsagar, Catriona Waitt, Olayinka O. Ogunleye, Lars L. Gustafsson   +5 more
wiley   +1 more source